In the Galician community, nine of the ten drugs with the highest cost are biological and account for around half of the cost of hospital treatment. For this reason, the arrival of the biosimilars it is seen as an 'opportunity' given the efficiency it brings. To take advantage of that opportunity, the Galician Health Service (Sergas) has set a market share target of 40 percent in defined daily doses (DDD). This was expressed by Antonio Fernández-Campa, manager of Sergas at the Meeting of Experts "The management of biosimilars in Galicia” organized by Diariofarma in Santiago de Compostela.

READ MORE